US 10988470
Pyrimidine compound as JAK kinase inhibitor
granted A61KA61K31/506A61K45/06
Quick answer
US patent 10988470 (Pyrimidine compound as JAK kinase inhibitor) held by Theravance Biopharma R&D IP, LLC expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Theravance Biopharma R&D IP, LLC
- Grant date
- Tue Apr 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 19
- CPC classes
- A61K, A61K31/506, A61K45/06, A61K9/0014, A61K9/06